U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H11NO4
Molecular Weight 197.1883
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVODOPA

SMILES

c1cc(c(cc1C[C@@]([H])(C(=O)O)N)O)O

InChI

InChIKey=WTDRDQBEARUVNC-LURJTMIESA-N
InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1

HIDE SMILES / InChI

Molecular Formula C9H11NO4
Molecular Weight 197.1883
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23948989 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021485s20lbl.pdf

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been widely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

Originator

Curator's Comment:: # Hoffmann-La Roche

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Stalevo

Approved Use

Stalevo® (carbidopa, levodopa and entacapone) is indicated to treat patients with idiopathic Parkinson’s disease.

Launch Date

1.0552032E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.946 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered: CARBIDOPA, DL-
LEVODOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
84.8 μg × min/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered: CARBIDOPA, DL-
LEVODOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
78.7 min
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered: CARBIDOPA, DL-
LEVODOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
80%
LEVODOPA plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
3 g 1 times / day multiple, oral
Dose: 3 g, 1 times / day
Route: oral
Route: multiple
Dose: 3 g, 1 times / day
Sources:
unhealthy, 54 years
n = 1
Health Status: unhealthy
Condition: idiopathic Parkinson's disease
Age Group: 54 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Alopecia...
AEs leading to
discontinuation/dose reduction:
Alopecia (1 patient)
Sources:
420 mg 1 times / day multiple, respiratory
Recommended
Dose: 420 mg, 1 times / day
Route: respiratory
Route: multiple
Dose: 420 mg, 1 times / day
Sources:
unhealthy, adult
84 mg 2 times / day multiple, respiratory
Recommended
Dose: 84 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 84 mg, 2 times / day
Sources:
unhealthy, adult
n = 114
Health Status: unhealthy
Condition: Parkinson’s disease
Age Group: adult
Population Size: 114
Sources:
Disc. AE: Cough...
AEs leading to
discontinuation/dose reduction:
Cough (2%)
Sources:
0.51 mg/kg 3 times / day steady, oral
Dose: 0.51 mg/kg, 3 times / day
Route: oral
Route: steady
Dose: 0.51 mg/kg, 3 times / day
Sources:
unhealthy, child|adult
n = 15
Health Status: unhealthy
Condition: Vision Impairment
Age Group: child|adult
Population Size: 15
Sources:
Other AEs: Headache, Nausea...
Other AEs:
Headache (below serious, 2 patients)
Nausea (below serious, 2 patients)
Sources:
0.76 mg/kg 3 times / day steady, oral
Dose: 0.76 mg/kg, 3 times / day
Route: oral
Route: steady
Dose: 0.76 mg/kg, 3 times / day
Sources:
unhealthy, child|adult
n = 15
Health Status: unhealthy
Condition: Vision Impairment
Age Group: child|adult
Population Size: 15
Sources:
Other AEs: Headache, Dry mouth...
Other AEs:
Headache (below serious, 1 patient)
Dry mouth (below serious, 2 patients)
Nausea (below serious, 1 patient)
Fatigue (below serious, 2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Alopecia 1 patient
Disc. AE
3 g 1 times / day multiple, oral
Dose: 3 g, 1 times / day
Route: oral
Route: multiple
Dose: 3 g, 1 times / day
Sources:
unhealthy, 54 years
n = 1
Health Status: unhealthy
Condition: idiopathic Parkinson's disease
Age Group: 54 years
Sex: F
Population Size: 1
Sources:
Cough 2%
Disc. AE
84 mg 2 times / day multiple, respiratory
Recommended
Dose: 84 mg, 2 times / day
Route: respiratory
Route: multiple
Dose: 84 mg, 2 times / day
Sources:
unhealthy, adult
n = 114
Health Status: unhealthy
Condition: Parkinson’s disease
Age Group: adult
Population Size: 114
Sources:
Headache below serious, 2 patients
0.51 mg/kg 3 times / day steady, oral
Dose: 0.51 mg/kg, 3 times / day
Route: oral
Route: steady
Dose: 0.51 mg/kg, 3 times / day
Sources:
unhealthy, child|adult
n = 15
Health Status: unhealthy
Condition: Vision Impairment
Age Group: child|adult
Population Size: 15
Sources:
Nausea below serious, 2 patients
0.51 mg/kg 3 times / day steady, oral
Dose: 0.51 mg/kg, 3 times / day
Route: oral
Route: steady
Dose: 0.51 mg/kg, 3 times / day
Sources:
unhealthy, child|adult
n = 15
Health Status: unhealthy
Condition: Vision Impairment
Age Group: child|adult
Population Size: 15
Sources:
Headache below serious, 1 patient
0.76 mg/kg 3 times / day steady, oral
Dose: 0.76 mg/kg, 3 times / day
Route: oral
Route: steady
Dose: 0.76 mg/kg, 3 times / day
Sources:
unhealthy, child|adult
n = 15
Health Status: unhealthy
Condition: Vision Impairment
Age Group: child|adult
Population Size: 15
Sources:
Nausea below serious, 1 patient
0.76 mg/kg 3 times / day steady, oral
Dose: 0.76 mg/kg, 3 times / day
Route: oral
Route: steady
Dose: 0.76 mg/kg, 3 times / day
Sources:
unhealthy, child|adult
n = 15
Health Status: unhealthy
Condition: Vision Impairment
Age Group: child|adult
Population Size: 15
Sources:
Dry mouth below serious, 2 patients
0.76 mg/kg 3 times / day steady, oral
Dose: 0.76 mg/kg, 3 times / day
Route: oral
Route: steady
Dose: 0.76 mg/kg, 3 times / day
Sources:
unhealthy, child|adult
n = 15
Health Status: unhealthy
Condition: Vision Impairment
Age Group: child|adult
Population Size: 15
Sources:
Fatigue below serious, 2 patients
0.76 mg/kg 3 times / day steady, oral
Dose: 0.76 mg/kg, 3 times / day
Route: oral
Route: steady
Dose: 0.76 mg/kg, 3 times / day
Sources:
unhealthy, child|adult
n = 15
Health Status: unhealthy
Condition: Vision Impairment
Age Group: child|adult
Population Size: 15
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[Abnormal movements induced by L-dopa. New therapeutic possibilities].
1975 Jan 25
The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?
1999
Levodopa-induced dyskinesias treated by pallidotomy.
1999 Aug 1
Risk factors for levodopa-induced dyskinesias in Parkinson's disease.
1999 Dec
Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study.
1999 Dec
Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.
1999 Jan-Feb
Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist.
1999 Jul 22
Worsening of levodopa-induced dyskinesias by motor and mental tasks.
1999 Mar
Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease.
1999 May 22
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
1999 Nov
Punding on L-dopa.
1999 Sep
[Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
2000
Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia.
2000
Quetiapine for l-dopa-induced psychosis in PD.
2000 Apr 11
Sleep attacks and Parkinson's disease treatment.
2000 Apr 15
[Dopaminergic agonists in the treatment of Parkinson's disease].
2000 Dec
Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease.
2000 Dec 26
Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease.
2000 Feb
Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease.
2000 Jul
Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration.
2000 Mar
[Treatment of advanced Parkinson's disease].
2000 Oct
Workshop IV: drug treatment guidelines for the long-term management of Parkinson's disease.
2000 Sep
Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.
2000 Sep
Apomorphine: an underutilized therapy for Parkinson's disease.
2000 Sep
Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.
2001
Melanogenesis by tyrosinase action on 3,4-dihydroxyphenylalanine (DOPA) in the presence of polyethylene glycol: a matrix-assisted laser desorption/ionization mass spectrometric investigation.
2001
Inhibition of potato polyphenol oxidase by anions and activity in various carboxylate buffers (pH 4.8) at constant ionic strength.
2001
SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.
2001 Aug
Dopamine D(2) receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum.
2001 Feb
Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease.
2001 Feb
Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase.
2001 Feb
Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease.
2001 Jan
SPECT imaging of the dopamine transporter in juvenile-onset dystonia.
2001 Jan 23
Comparative analysis of the gait disorder of normal pressure hydrocephalus and Parkinson's disease.
2001 Mar
The effect of levodopa on vocal function in Parkinson's disease.
2001 Mar-Apr
Parkinsonism after glycine-derivate exposure.
2001 May
Speech dysfluency exacerbated by levodopa in Parkinson's disease.
2001 May
Chromium(VI) reduction by catechol(amine)s results in DNA cleavage in vitro: relevance to chromium genotoxicity.
2001 May
Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions.
2008 Dec 3
Patents

Sample Use Guides

Maximum dosage in a 24-hour period is eight tablets (Stalevo 50, containing 12.5 mg of carbidopa, 50 mg of levodopa and 200 mg of entacapone; Stalevo 75, containing 18.75 mg of carbidopa, 75 mg of levodopa and 200 mg of entacapone; Stalevo 100, containing 25 mg of carbidopa, 100 mg of levodopa and 200 mg of entacapone; Stalevo 125, containing 31.25 mg of carbidopa, 125 mg of levodopa and 200 mg of entacapone; Stalevo 150, containing 37.5 mg of carbidopa, 150 mg of levodopa and 200 mg of entacapone; Stalevo 200, containing 50 mg of carbidopa, 200 mg of levodopa and 200 mg of entacapone). The optimum daily dosage must be determined by careful titration in each patient.
Route of Administration: Oral
Low dose (<30 uM) Levodopa protects PC12 cells against oxidative stress which might be related to the up-regulation of CD39 and pCREB expression.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:59:09 UTC 2021
Edited
by admin
on Fri Jun 25 20:59:09 UTC 2021
Record UNII
46627O600J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEVODOPA
EMA EPAR   EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
LEVODOPA [JAN]
Common Name English
RYTARY COMPONENT LEVODOPA
Brand Name English
CARBILEV COMPONENT LEVODOPA
Common Name English
LEVODOPA [INN]
Common Name English
LEVODOPA COMPONENT OF SINEMET
Common Name English
V-1512
Code English
LEVODOPA [WHO-IP]
Common Name English
LEVODOPA [ORANGE BOOK]
Common Name English
CORBILTA COMPONENT LEVODOPA
Brand Name English
LEVODOPA [EMA EPAR]
Common Name English
L-DOPA
Systematic Name English
LEVODOPA [USP-RS]
Common Name English
LEVODOPA COMPONENT OF DUOPA
Brand Name English
BENDOPA
Brand Name English
LEVODOPA COMPONENT OF STALEVO
Brand Name English
LEVODOPA [USAN]
Common Name English
LEVODOPA COMPONENT OF DOPASNAP
Common Name English
LEVODOPA [USP MONOGRAPH]
Common Name English
LEVODOPA/CARBIDOPA/ENTACAPONE ORION COMPONENT LEVODOPA
Brand Name English
LEVODOPA COMPONENT OF CORBILTA
Brand Name English
STALEVO COMPONENT LEVODOPA
Brand Name English
LEVODOPA COMPONENT OF PARCOPA
Common Name English
LARODOPA
Brand Name English
LEVODOPA [WHO-DD]
Common Name English
LEVODOPA COMPONENT OF LEVODOPA/CARBIDOPA/ENTACAPONE ORION
Brand Name English
IPX203 COMPONENT LEVODOPA
Common Name English
DOPAR
Brand Name English
DUOPA COMPONENT LEVODOPA
Brand Name English
PARCOPA COMPONENT LEVODOPA
Common Name English
LEVODOPA [EP]
Common Name English
LEVODOPA [HSDB]
Common Name English
LEVODOPA [EP MONOGRAPH]
Common Name English
IPX-203 COMPONENT LEVODOPA
Common Name English
LEVODOPA [MI]
Common Name English
LEVODOPA COMPONENT OF CARBILEV
Common Name English
DIHYDROXYPHENYLALANINE
Systematic Name English
NSC-118381
Code English
(-)-3-(3,4-DIHYDROXYPHENYL)-L-ALANINE
Systematic Name English
LEVODOPUM [WHO-IP LATIN]
Common Name English
LEVODOPA COMPONENT OF RYTARY
Brand Name English
L-TYROSINE, 3-HYDROXY-
Systematic Name English
DOPASNAP COMPONENT LEVODOPA
Common Name English
DOPA, L-
Systematic Name English
CVT-301
Common Name English
LEVODOPA [MART.]
Common Name English
INBRIJA
Brand Name English
LEVODOPA [VANDF]
Common Name English
Classification Tree Code System Code
WHO-VATC QN04BA03
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
DSLD 1198 (Number of products:24)
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 09 (LEV/CAR)
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
EMA ASSESSMENT REPORTS CORBILTA (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
EU-Orphan Drug EU/3/01/035
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
EMA ASSESSMENT REPORTS STALEVO (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
WHO-ATC N04BA01
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
EMA ASSESSMENT REPORTS CORBILTA (AUTHORIZED: NEURODEGENERATIVE DISEASES)
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
WHO-VATC QN04BA02
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
WHO-ATC N04BA03
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
WHO-VATC QN04BA01
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
LOINC 79577-3
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
NDF-RT N0000193220
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
LIVERTOX 552
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
FDA ORPHAN DRUG 129499
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
NDF-RT N0000175754
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
WHO-ATC N04BA02
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
NCI_THESAURUS C66884
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
NDF-RT N0000175755
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
EMA ASSESSMENT REPORTS LEVODOPA/CARBIDOPA/ENTACAPONE ORION (AUTHORIZED: PARKINSON DISEASE)
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
EMA ASSESSMENT REPORTS CORBILTA (AUTHORIZED: NERVOUS SYSTEM DISEASES)
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
Code System Code Type Description
PUBCHEM
6047
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY
WIKIPEDIA
L-DOPA
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY
LACTMED
Levodopa
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
LEVODOPA
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY Description: A white or almost white, crystalline powder; odourless. Solubility: Soluble in 300 parts of water; practically insoluble in ethanol (~750 g/l) TS and ether R. Category: Antiparkinsonism drug. Storage: Levodopa should be kept in a tightly closed container.Definition: Levodopa contains not less than 98.5% and not more than 101.0% of C9H11NO4, calculated with reference to the dried substance.
MESH
D007980
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY
DRUG CENTRAL
1567
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY
NCI_THESAURUS
C611
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY
EVMPD
SUB08468MIG
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY
EPA CompTox
59-92-7
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY
FDA UNII
46627O600J
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY
ChEMBL
CHEMBL1009
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY
HSDB
3348
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY
USP_CATALOG
1361009
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY USP-RS
IUPHAR
3639
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY
MERCK INDEX
M6786
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY Merck Index
INN
2651
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-445-2
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY
CAS
59-92-7
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY
DRUG BANK
DB01235
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY
RXCUI
6375
Created by admin on Fri Jun 25 20:59:09 UTC 2021 , Edited by admin on Fri Jun 25 20:59:09 UTC 2021
PRIMARY RxNorm
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
PARENT -> CONSTITUENT ALWAYS PRESENT
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
TARGET -> AGONIST
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
METABOLITE ACTIVE -> PRODRUG
METABOLITE ACTIVE -> PRODRUG
MAJOR
METABOLITE -> PARENT
When decarboxylation of levodopa is prevented by carbidopa, COMT becomes the major metabolizing enzyme for levodopa, catalyzing its metabolism to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD).
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 2.2
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY